Clinical Trials
59 trialsNCT03907488 2026-06-01
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01476410 2026-05-22
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Completed
NCT01920932 2026-05-06
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT05269355 2025-06-13
SUNRISELMS
PTC Therapeutics
Phase 2/3 Terminated
NCT01716806 2024-06-11
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Phase 2 Completed
NCT02181738 2023-11-28
CheckMate 205
Bristol-Myers Squibb
Phase 2 Completed
NCT01152788 2023-08-22
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003389 2023-06-29
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03226249 2023-06-02
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
NCT00822120 2022-08-18
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01835145 2022-08-04
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01721772 2022-07-12
CheckMate 066
Bristol-Myers Squibb
Phase 3 Completed
NCT00130442 2022-06-23
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Cellxpert Biotechnology Corp.
Phase 2 Completed
NCT01721746 2022-04-19
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb
Phase 3 Completed
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT02505269 2020-08-24
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT02545075 2020-05-19
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Bristol-Myers Squibb
Phase 3 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00864253 2019-10-30
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Celgene
Phase 3 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01542255 2019-01-15
Metronomic Therapy in Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT00369681 2018-08-27
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00089544 2018-04-13
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01534078 2018-02-20
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT01693068 2018-01-05
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
EMD Serono
Phase 2 Completed
NCT01227889 2017-10-04
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00849875 2017-07-12
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
GlaxoSmithKline
Phase 2 Terminated
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01164007 2017-04-21
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT00802880 2017-02-13
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT01974752 2017-01-05
SUMIT
AstraZeneca
Phase 3 Completed
NCT01133977 2016-10-10
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai Inc.
Phase 1/2 Completed
NCT01006980 2016-09-28
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche
Phase 3 Completed
NCT01343277 2016-08-26
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT00837148 2015-11-20
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01681212 2015-06-11
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed